Stephen Basil Thomas - 15 Sep 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: Director
Issuer ticker: CLYM
Reported as of: 15 Sep 2026
Net transaction value: -$1,366,820
SEC form: 4
Accepted by SEC: 17 Sep 2026, 16:15:05 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Chandra Adams, as Attorney-in-Fact

Key filing fact

Stephen Basil Thomas filed Form 4 for Climb Bio, Inc. (CLYM) on 17 Sep 2026.

Key facts

This page summarizes Stephen Basil Thomas's Form 4 filing for Climb Bio, Inc. (CLYM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Sep 2026, 16:15.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: -$1,366,820.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002027962 Primary reporting owner

Thomas Stephen Basil

Relationship: Director
Address: C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS
Signature: /s/ Chandra Adams, as Attorney-in-Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLYM transaction

Common Stock

Sale

Transaction value: $1,366,820
Shares: -100,000
Change %: -18%
Price: $13.67
Shares after: 467,969
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.